One means of doing this could be to use an anti-IL-1β antibody such as Anakinra, which has already been demonstrated to be effective in reducing rates of heart failure in cases of myocardial infarction, while not significantly increasing infection rates.40,41 We feel that EVLP provides an ideal means to administer therapeutic modulation before transplantation in the future. The gene discussed is IL1B; the disease is heart failure.